Helus Pharma Pops 11% on Depression Drug Data Blitz, but Can It Keep Up in a Crowding Psychedelic Race?

Shares shifted sharply higher Monday as Helus Pharma (ticker: HELP), the company formerly known as Cybin, unveiled four research presentations at Psych Congress 2026 showcasing its lead depression drug — a psilocybin-derived pill designed to work alongside existing antidepressants rather than replace them. The stock jumped 10.8% to $13.70, but the real question for shareholders is whether the make-or-break trial results due later this year can justify a valuation that has already more than doubled since February.

• Twelve Months of Data Build the Bull Case — Now Phase 3 Must Deliver. Three of the four posters extended findings from an earlier mid-stage trial, including 12-month efficacy data that previously showed roughly 13- to 14-point improvements on a standard depression scale and remission rates above 70% through one year after just two doses . Those are eye-catching numbers, but they come from a small study. The pivotal APPROACH trial enrolled 223 patients and will report six-week and 12-week results in Q4 2026. If the drug's effect shrinks in a larger, more rigorous test — a common outcome in psychiatry — the stock's rally could unwind fast.

• A $166 Million Cash Cushion Buys Time, Not Certainty. The company's cash position stood at $166.4 million as of June 30, 2026 , bolstered by a $50 million raise in June . That provides runway through the data readout, but Helus is burning cash quickly — trailing-twelve-month net loss hit $171.2 million . A second large trial, EMBRACE, plans to enroll 330 patients across the U.S., Europe, and Australia , meaning another capital raise is likely before any approval.

• Big Pharma Money Is Flooding Into Competing Drugs. Otsuka acquired Transcend Therapeutics for $1.2 billion and AbbVie bought Gilgamesh Pharmaceuticals' psychedelic compound for $1.2 billion . Compass Pathways is mid-rolling-submission to the FDA for its psilocybin candidate , and Definium's LSD-derived drug posted an 8.1-point placebo-adjusted improvement in Phase 3 . Helus must prove its add-on approach — letting patients stay on current medications — offers a meaningfully distinct advantage.

• Analyst Targets Signal Optimism, but the Gap Is Enormous. Barclays initiated coverage on September 18 with an Overweight rating and a $35 price target , while TD Cowen raised its target to $62 from $8 in August . Those figures imply the stock could triple or quadruple — but only if Phase 3 works. The company is targeting a potential 2028 U.S. approval . Until the Q4 data drop, today's pop is a down payment on a promise, not proof.